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 Background The etiology of renal cell carcinoma (RCC) is only partially understood, but a metabolic component appears likely. 
We investigated biomarkers of one-carbon metabolism and RCC onset and survival.
 Methods The European Prospective Investigation into Cancer and Nutrition (EPIC) recruited 385 747 participants with blood 
samples between 1992 and 2000, and this analysis included 556 RCC case-control pairs. A subsequent replication 
study included 144 case-control pairs nested within the Melbourne Collaborative Cohort Study (MCCS). Plasma 
concentrations of vitamin B2, vitamin B6, folate, vitamin B12, methionine and homocysteine were measured 
in prediagnostic samples and evaluated with respect to RCC risk using conditional and unconditional logistic 
regression models, and to all-cause mortality in RCC cases using Cox regression models. All statistical tests were 
two-sided.
 Results EPIC participants with higher plasma concentrations of vitamin B6 had lower risk of RCC, the odds ratio compar-
ing the 4th and 1st quartiles (OR4vs1) being 0.40 95% confidence interval [CI] = 0.28 to 0.57, Ptrend < .001. We found 
similar results after adjusting for potential confounders (adjusted Ptrend < .001). In survival analysis, the hazard 
ratio for all-cause mortality in RCC cases when comparing the 4th and 1st quartiles (HR4vs1) of vitamin B6 was 0.57 
(95% CI = 0.37 to 0.87, Ptrend < .001).
  Subsequent replication of these associations within the MCCS yielded very similar results for both RCC risk 
(OR4vs1  =  0.47, 95% CI  =  0.23 to 0.99, Ptrend  =  .07) and all-cause mortality (HR4vs1  =  0.56, 95% CI  =  0.27 to 1.17, 
Ptrend = .02). No association was evident for the other measured biomarkers.
 Conclusion Study participants with higher circulating concentrations of vitamin B6 had lower risk of RCC and improved sur-
vival following diagnosis in two independent cohorts.
  JNCI J Natl Cancer Inst (2014) 106(12): dju327 doi:10.1093/jnci/dju327
The etiology of kidney cancer is not well understood, and there 
are notable unexplained differences in incidence. The high-
est rates worldwide are observed in the Czech Republic (1), and 
in the United States; the age-standardized rates (ASR) of kidney 
cancer are approximately two-fold higher for African Americans 
and European Americans than for Asians (2). Renal cell carcinoma 
(RCC) is the predominant type of kidney cancer and accounts for 
approximately 80% of cases (2).
Established risk factors for RCC include tobacco smoking, obe-
sity, and hypertension, as well as recently discovered gene variants 
(2–4). Additionally, it has been suggested that diabetes mellitus may 
increase RCC risk, whereas lifestyle factors such as high physical 
activity, alcohol, and intake of fruits and vegetables may reduce 
risk (2). The relation between fruit and vegetable intake and RCC 
is intriguing and consistently observed in both retrospective and 
prospective case-control studies (5). While residual confounding 
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by tobacco smoking is of concern in the interpretation of these 
studies, a causal association cannot be excluded (6–8).
Fruits and vegetables are sources of B vitamins and other com-
ponents of the one-carbon metabolism pathway, which is important 
in maintaining DNA methylation and DNA repair mechanisms in 
the body (9,10). Circulating concentrations of B-vitamins have 
been investigated in relation to multiple cancers, but only one pro-
spective study has been published for RCC (11).
We sought to investigate whether concentrations of circulating 
B-vitamins and amino acids in the one-carbon metabolism pathway 
are related to RCC incidence and outcome using a large European 
cohort. To ensure the validity of our findings, we also conducted a 
replication of promising results within a separate Australian cohort.
Methods
Study Cohort—The European Prospective Investigation 
into Cancer and Nutrition (EPIC)
The EPIC study recruitment procedures have been previously 
described in detail (12), and important cohort information and 
follow-up procedures are provided in the Supplementary Methods 
(available online).
Selection of Cases and Controls
We initially identified 905 cases within EPIC that were diagnosed 
with RCC as C64.9 according to the International Classification of 
Diseases for Oncology, Second Edition (ICD-O-2). After excluding 
prevalent cases and cases with a prior history of another cancer (n = 85, 
except nonmelanoma skin cancer), cases who did not donate a blood 
sample (n = 153), were not histologically confirmed (n = 27), did not 
have questionnaire information available (n = 6), and cases from the 
Malmö center that did not participate in this study (n = 64), 570 RCC 
cases remained eligible.
For each case, one control was randomly chosen from risk sets 
consisting of all cohort members alive and free of cancer (except 
nonmelanoma skin cancer) at the time of diagnosis of the index 
case. Matching criteria were: country, sex, date of blood collection 
(± one month, relaxed to ± five months for sets without available 
controls), and date of birth (± one year, relaxed to ± five years). 
Additionally, we included 553 controls (control group 2) matched 
to cases of a parallel study of head and neck cancer using identi-
cal matching criteria. Biochemical analyses were undertaken in the 
same laboratory under the same conditions, and at the same time 
for all cases and controls.
After excluding sets with only one case or control, 556 case-
control sets remained, as well as 553 additional unmatched controls 
from control group 2 that contributed to unconditional and strati-
fied analyses.
Replication Study—The Melbourne Collaborative Cohort 
Study (MCCS)
To replicate promising associations, we designed a case-control 
study nested within the MCCS. Extensive details on recruit-
ment and follow-up have been published previously (also see 
Supplementary Methods, available online) (13,14). Incident cases 
and controls were selected using the same protocol as the EPIC 
study. A total of 144 case-control pairs were available. The MCCS 
data were used as an independent replication analysis and were not 
pooled with the EPIC data.
Biochemical Analyses
Plasma samples were sent on dry ice to the Bevital A/S laboratory 
(http://www.bevital.no) in Bergen, Norway, where vitamin B2 (ribo-
flavin), vitamin B6 (measured as pyridoxal 5’-phosphate, its active 
form), folate (vitamin B9), vitamin B12 (cobalamin), total homo-
cysteine, and methionine were measured. Cotinine was measured as 
an indicator of recent smoking behavior. Details of the biochemical 
analyses are provided in Supplementary Methods (available online) 
(15–19).
Statistical Analyses
Quartiles of plasma concentrations for each biomarker were cal-
culated based on the distribution among controls. Odds ratios 
(ORs) and 95% confidence intervals (CIs) of RCC were calculated 
relative to the first quartile using conditional logistic regression, 
conditioning on individual case set. Log-linear trends (Ptrend) were 
calculated by including the base 2 logarithm (log2) of the biomarker 
concentration as a continuous variable in separate models.
To assess the consistency of any association, we compared 
RCC cases with the additional unmatched controls (control group 
2) using unconditional logistic regression, adjusting for sex, coun-
try, and age at recruitment (five-year groups). We also compared 
the RCC cases with all EPIC controls in order to increase the 
statistical power.
To evaluate whether known risk factors of RCC could explain 
any association, we assessed if OR estimates were affected after 
including indicator variables in the logistic regression models for 
tobacco smoking (smoking status at baseline [never, former, cur-
rent] and quartiles of cotinine concentrations [determined by the 
distribution for current smokers]), alcohol intake at recruitment 
(g/day), lifetime alcohol intake [ever/never], obesity (indicated 
by body mass index [BMI], five categories: <18.5, 18.5–25, 25–30, 
30–35, ≥35 kg/m2), educational attainment (in four categories), 
waist-to-hip ratio (quartiles), and self-reported history of hyper-
tension (yes/no). Missing values for these covariates were imputed 
under a multivariable normal model. One hundred imputations 
were drawn from the imputation model, which included all covari-
ates and biomarkers, as well as the case-control status. For binary 
and categorical covariates, we rounded imputed values to the near-
est integer category (20,21). As a sensitivity analysis, we also fitted 
models excluding observations with missing covariate data.
To assess potential effect modification, we performed stratified 
analyses by country of recruitment, smoking status, age at diagno-
sis, sex, education, time from blood draw to diagnosis, and waist-to-
hip ratio. These analyses included the log2 of each biomarker as a 
continuous covariates in unconditional logistic regression models. 
χ2 tests were applied to assess heterogeneity between ORs.
Hazard ratios (HRs) for all-cause mortality for RCC cases were 
calculated using Cox proportional hazards models. Time since 
diagnosis was used as the timescale, and all models were adjusted 
for age at diagnosis, sex, and country. Further adjustment was 
undertaken for tobacco smoking, alcohol intake at recruitment, 
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education, hypertension, and waist-to-hip ratio. Tests for trend 
were based on models including log2 of the biomarker concentra-
tions. Visual inspection of smoothed, scaled Schoenfeld residuals 
revealed no notable departure from proportional hazards. Model 
based estimates of the survival function by biomarker quartiles 
were calculated using flexible parametric survival models (22). 
Restricted cubic splines with five knots (placed at evenly spaced 
centiles of the uncensored log survival times) were used to model 
the baseline hazard.
Among the matched controls, partial correlation coefficients 
(conditional on country, age, and sex) were calculated between log-
transformed biomarker concentrations and dietary intake of fruits, 
vegetables, meats, and dairy products, as well as alcohol intake, cir-
culating cotinine, BMI, and waist-to-hip ratio. All P values were 
two-sided. Statistical analyses were conducted using SAS 9.2 (Cary, 
NC) and Stata 12.1 for Linux (Stata Corporation).
results
The EPIC Study Population
Baseline and demographic characteristics of the EPIC study popu-
lation are displayed in Table 1. Of the individually matched cases 
and controls, 56% were men and 44% were women. Median age at 
recruitment was 57 years (5th-95th percentile: 42–67), and average 
time from blood draw to RCC diagnosis was 6.7  years. Control 
group 2 included an additional 553 subjects with similar demo-
graphic characteristics as the matched control group, albeit with 
a higher proportion of men (68%). Known risk factors of RCC 
displayed expected differences between cases and controls, includ-
ing waist-to-hip ratio, BMI, smoking status, and hypertension. 
No substantial correlations were observed between one-carbon 
metabolism biomarkers and dietary intake of major food groups, 
circulating cotinine, alcohol intake, BMI, or waist-to-hip ratio 
(Supplementary Table 1, available online).
Plasma Concentrations of One-Carbon Metabolism 
Biomarkers and Risk of RCC
Initial conditional risk analysis was conducted by comparing cases 
and matched controls for quartiles of plasma biomarkers of one-
carbon metabolism (Table 2). Concentrations of vitamin B2, folate, 
B12, homocysteine and methionine displayed weak or no evidence 
of association with RCC risk (Ptrend > .06). In contrast, participants 
with higher concentrations of vitamin B6 had a lower risk of RCC 
in a dose response fashion (Ptrend < .001), the OR when compar-
ing the 4th and 1st quartiles (OR4vs1) being 0.40 (95% CI = 0.28 to 
0.57). Adjusting for potential confounders did not notably affect 
the OR estimates (adjusted OR4vs1 = 0.43, 95% CI = 0.29 to 0.64, 
Ptrend < .001) (Table 2). In a sensitivity analysis in which participants 
with missing covariate information were excluded, the correspond-
ing adjusted OR4vs1 was 0.34 (95% CI = 0.21 to 0.57, Ptrend < .001) 
(Supplementary Table 2, available online).
After accounting for vitamin B6, the other plasma biomarkers 
(vitamin B2, folate, B12, homocysteine and methionine) did not 
display any association with RCC risk (data not shown).
When comparing RCC cases with control group 2, we observed 
similar associations (Supplementary Table  2, available online). 
After combining all EPIC controls in an unconditional analysis the 
unadjusted OR4vs1 was 0.43 (95% CI = 0.32 to 0.60, Ptrend < .001) 
and 0.49 (95% CI = 0.35 to 0.68, Ptrend < .001) after adjusting for 
risk factors (Supplementary Table 2, available online).
Replication Study
In order to determine if the inverse relation between vitamin B6 
and risk of RCC was restricted to the EPIC study population, we 
analyzed plasma concentrations of vitamin B6 and cotinine in 144 
additional case-control pairs nested within the MCCS. The distri-
bution of vitamin B6 within the MCCS was similar to that within 
EPIC; hence, the same quartile cutoff points were applied. We 
obtained very similar OR estimates of RCC for quartiles of vitamin 
B6 within the MCCS, the OR4vs1 being 0.47 (95% CI  =  0.23 to 
0.99), after adjusting for available risk factors (Table 3).
Associations With a Doubling of Plasma Vitamin B6 
Levels
A doubling in plasma vitamin B6 was associated with a 20% lower 
odds of RCC in MCCS (OR for log2B6 [ORlog2]  =  0.80, 95% 
CI = 0.64 to 1.02, Ptrend =  .07) and a 22% lower odds in EPIC 
(ORlog2 = 0.78, 95% CI = 0.63 to 0.82, Ptrend < .001). The corre-
sponding unadjusted ORlog2 estimates after stratifying by various 
descriptive variables within EPIC are displayed in Figure 1. The 
association between concentrations of vitamin B6 and RCC risk 
was marginally more prominent for men than women, for cur-
rent smokers than former and never smokers, and for subjects 
that were not hypertensive. The ORlog2 for vitamin B6 among 
current smokers, after adjusting for hypertension, waist-to-hip 
ratio, educational attainment, alcohol intake, BMI, and circulat-
ing cotinine was 0.52 (95% CI = 0.39 to 0.71). Additional adjust-
ment for number of cigarettes smoked per day and duration of 
smoking did not affect the estimate (ORlog2 = 0.53, 95% CI = 0.39 
to 0.72). We further note that the association between vitamin 
B6 and risk was evident when evaluating blood samples taken up 
to ten years prior to diagnosis (Figure 1). Circulating concentra-
tions of vitamin B6 by demographic variables, risk factors, and 
tumor stage are provided in Supplementary Table  3 (available 
online).
All-Cause Mortality for RCC Cases
Results of Cox proportional hazards regression for all-cause 
mortality (205 deaths in total) are shown in Table  4 and 
Supplementary Table  4 (available online). For vitamin B6 the 
HR for all-cause mortality for RCC cases when comparing the 
4th and 1st quartiles was 0.57 (95% CI = 0.37 to 0.87) (Table 4). 
The corresponding Ptrend was less than .001, and the trend HR 
for log2B6 (HRlog2) was 0.74 (95% CI = 0.62 to 0.88). This result 
was nearly identical when excluding cases diagnosed within 
two years of blood draw (HRlog2 = 0.73, 95% CI = 0.60 to 0.90, 
Ptrend  =  .003). For RCC cause-specific mortality (147 deaths), 
the HR4vs1 was 0.36 (95% CI = 0.20 to 0.65), the corresponding 
HRlog2 was 0.64 (95% CI = 0.52 to 0.79, Ptrend <.001). For com-
parison, we observed 36 deaths among the matched controls and 
the corresponding HRlog2 of all-cause mortality was 1.01 (95% 
CI = 0.71 to 1.45, Ptrend = .95). Adjusting the all-cause mortality 
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Table 1. Baseline and demographic characteristics of the study participants from EPIC
RCC cases Matched controls Control group 2
Continuous variables No. (%), n = 556 No. (%), n = 556 No. (%), n = 553
Sex*
 Men 310 (56%) 310 (56%) 374 (67.6%)
 Women 246 (44%) 246 (44%) 179 (32.4%)
Participating countries*
 France 13 (2%) 13 (2%) 7 (1.3%)
 Italy 88 (16%) 88 (16%) 70 (13%)
 Spain 52 (9%) 52 (9%) 100 (18%)
 United Kingdom 67 (12%) 67 (12%) 130 (24%)
 The Netherlands 46 (8%) 46 (8%) 77 (14%)
 Greece 17 (3%) 17 (3%) 22 (4%)
 Germany 125 (22%) 125 (22%) 104 (19%)
 Sweden 32 (6%) 32 (6%) 41 (7%)
 Denmark 112 (20%) 112 (20%)
 Norway 4 (1%) 4 (1%) 2 (0.4%)
Smoking status
 Never smokers 225 (41%) 244 (44%) 230 (42%)
 Former smokers 160 (29%) 180 (32%) 199 (36%)
  Years since quitting ≥10 94 (58%) 122 (68%) 135 (68%)
  Years since quitting <10 66 (42%) 58 (32%) 64 (33%)
 Current smokers 166 (30%) 129 (23%) 110 (20%)
 Unknown 5 (1%) 3 (1%) 14 (3%)
Educational attainment
 Primary school 229 (41%) 206 (37%) 222 (40%)
 Technical/professional school 124 (22%) 136 (25%) 141 (26%)
 Secondary school 77 (14%) 66 (12%) 70 (13%)
 Higher education 110 (20%) 134 (24%) 99 (18%)
 Unknown 16 (3%) 14 (3%) 21 (4%)
Body mass index, kg/m2
 <18.5 2 (0%) 2 (0%) 5 (1%)
 18.5–25 179 (32%) 221 (40%) 215 (39%)
 25–30 247 (45%) 241 (43%) 258 (47%)
 30–35 99 (18%) 69 (12%) 61 (11%)
 ≥35 29 (5%) 23 (4%) 14 (3%)
Waist-to-hip ratio
 0.56–0.79 92 (17%) 113 (20%) 86 (16%)
 0.80–0.89 129 (23%) 145 (26%) 146 (26%)
 0.90–0.94 103 (19%) 114 (21%) 128 (23%)
 0.95–1.30 196 (35%) 148 (27%) 150 (27%)
 Unknown 36 (7%) 36 (7%) 43 (8%)
Hypertension
 No 276 (50%) 325 (59%) 318 (58%)
 Yes 192 (35%) 140 (25%) 115 (21%)
 Unknown 88 (16%) 91 (16%) 120 (22%)
Alcohol intake
 Never drinkers 37 (7%) 22 (4%) 28 (5%)
 Ever drinkers 509 (92%) 530 (95%) 520 (94%)
 Unknown 10 (2%) 4 (1%) 5 (1%)
Alcohol intake at recruitment*
 <5 g/day 248 (45%) 221 (40%) 235 (43%)
 5–20 g/day 156 (28%) 173 (30%) 168 (30%)
 ≥20 g/day 152 (27%) 162 (30%) 150 (27%)
Continuous variables Median (5th–95th percentile)
Age at recruitment, y 56.9 (42–67) 56.9 (41.8–67.3) 56.6 (41.0–70.6)
Age at diagnosis, y 63.7 (49–75) - -
Time from blood draw to diagnosis, y 6.7 (1–12) - -
Plasma concentrations for components of the one-carbon metabolism
 Vitamin B2 (Riboflavin), nmol/L 13.9 (5.2–47.8) 14.4 (5.8–48.0) 13.2 (5.9–48.1)
 Vitamin B6 (Pyridoxal 5’-phosphate), 
nmol/L
30.3 (13.0–89.0) 35.9 (14.6–122) 34.8 (14.3–97.0)
 Folate (Vitamin B9), nmol/L 11.3 (3.9–32.2) 11.9 (4.5–36.6) 13.0 (5.1–35.6)
(Table continues)
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Table 2. Odds ratios of RCC for plasma concentrations of vitamins B2, B6, folate, B12, and homocycteine and methionine in the EPIC study
Quartile (range) Cases, No. (%) Controls, No. (%)
Odds ratio (95% confidence interval)
Unadjusted conditional 
risk analysis*
Conditional risk analysis 
adjusted for risk factors†
(n = 556/556)* (n = 556/556)†
Vitamin B2 (Riboflavin), nmol/L‡
 1 (2.57–9.83) 164 (30) 139 (25) 1.00 (referent) 1.00 (referent)
 2 (9.84–14.3) 132 (24) 139 (25) 0.80 (0.57 to 1.12) 0.81 (0.56 to 1.16)
 3 (14.4–22.2) 133 (24) 139 (25) 0.81 (0.58 to 1.13) 0.79 (0.56 to 1.13)
 4 (22.2–416) 127 (23) 139 (25) 0.77 (0.55 to 1.09) 0.81 (0.56 to 1.17)
Ptrend§ .13 .26
Vitamin B6 (Pyridoxal 5’-phosphate), nmol/L‡
 1 (5.95–25.4) 210 (38) 138 (25) 1.00 (referent) 1.00 (referent)
 2 (25.4–35.9) 136 (25) 139 (25) 0.66 (0.48 to 0.91) 0.69 (0.49 to 0.98)
 3 (35.9–51.9) 120 (22) 139 (25) 0.55 (0.39 to 0.77) 0.62 (0.43 to 0.89)
 4 (51.9–436) 90 (16) 139 (25) 0.40 (0.28 to 0.57) 0.43 (0.29 to 0.64)
Ptrend§ <.001 <.001
Vitamin B9 (Folate), nmol/L‡
 1 (0.20–8.40) 152 (27) 138 (25) 1.00 (referent) 1.00 (referent)
 2 (8.41–11.8) 138 (25) 139 (25) 0.88 (0.62 to 1.24) 0.96 (0.66 to 1.40)
 3 (11.9–17.3) 134 (24) 139 (25) 0.85 (0.59 to 1.22) 0.96 (0.65 to 1.43)
 4 (17.3–109) 131 (24) 139 (25) 0.81 (0.55 to 1.20) 0.84 (0.55 to 1.27)
Ptrend§ .08 .11
Vitamin B12 (Cobalamin), pmol/L‡
 1 (75.2–281) 154 (28) 138 (25) 1.00 (referent) 1.00 (referent)
 2 (281–343) 148 (27) 139 (25) 0.96 (0.69 to 1.33) 0.96 (0.67 to 1.37)
 3 (344–419) 137 (25) 139 (25) 0.88 (0.63 to 1.24) 0.87 (0.61 to 1.26)
 4 (419–5000) 116 (21) 139 (25) 0.74 (0.52 to 1.05) 0.67 (0.46 to 0.99)
Ptrend§ .12 .06
Methionine, µmol/L‡
 1 (2.1–21.48) 151 (27) 138 (25) 1.00 (referent) 1.00 (referent)
 2 (21.5–25) 166 (30) 140 (25) 1.03 (0.74–1.44) 1.07 (0.75 to 1.52)
 3 (25.01–28.94) 115 (21) 140 (25) 0.70 (0.49–1.01) 0.70 (0.47 to 1.03)
 4 (28.95–71.4) 124 (22) 138 (25) 0.77 (0.53–1.11) 0.80 (0.53 to 1.19)
Ptrend§ .06 .10
Homocysteine, µmol/L‡
 1 (3.68–8.03) 141 (25) 138 (25) 1.00 (referent) 1.00 (referent)
 2 (8.04–9.87) 157 (28) 140 (25) 1.11 (0.79 to 1.56) 1.00 (0.69 to 1.43)
 3 (9.88–11.9) 114 (21) 138 (25) 0.81 (0.56 to 1.17) 0.73 (0.49 to 1.09)
 4 (12.0–64.9) 144 (26) 139 (25) 1.02 (0.69 to 1.51) 0.85 (0.56 to 1.30)
Ptrend§ .55 .98
* Assessed by analyzing renal cell carcinoma (RCC) cases and their individually matched controls by conditional logistic regression, conditioning on individual case 
set. EPIC = European Prospective Investigation into Cancer and Nutrition.
† Assessed by analyzing RCC cases and their individually matched controls by conditional logistic regression after multiple imputation of missing covariate data, 
conditioning on individual case set, and adjusting for waist-to-hip ratio (quartiles defined among matched controls), hypertension (yes/no), educational attainment 
(four categories), smoking status (never/former/current), plasma cotinine (quartiles defined by the distribution for current smokers), alcohol intake at recruitment 
(g/day) and alcohol intake (ever/never). Case-control numbers only include those case sets where both the case and matched control had complete plasma 
measurements.
‡ Quartile cutoff points were determined based on the plasma level distribution of each biomarker for 556 individually matched controls.
§ Ptrend assessed by the base 2 logarithm of plasma concentrations. All statistical tests were two-sided.
RCC cases Matched controls Control group 2
Continuous variables No. (%), n = 556 No. (%), n = 556 No. (%), n = 553
 Vitamin B12 (cobalamin), pmol/L 332 (192–582) 344 (194–588) 329 (178–523)
 Methionine, µmol/L 24.1 (16.3–38.1) 25.0 (16.9–37.0) 25.1 (17.2–37.9)
 Homocysteine, µmol/L 9.6 (6.2–18.4) 9.9 (6.1–17.3) 10.1 (6.4–18.4)
* Matching criteria were country, sex, and age at recruitment. EPIC = European Prospective Investigation into Cancer and Nutrition.
Table 1. (Continued).
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analysis for potential confounders did not notably affect the HR 
estimates (Table  4). Model-based survival curves and Kaplan-
Meier estimates are presented in Figure  2. Five-year survival 
proportions were 57% (95% CI = 50% to 64%) for RCC cases in 
the bottom 25% of plasma vitamin B6 and 73% (95% CI = 62% 
to 81%) for RCC cases in the upper 25% of plasma vitamin 
Table 3. Odds ratios of RCC for plasma concentrations of vitamin B6 for participants in the MCCS study
 Quartile (range)  Cases, No. (%) Controls, No. (%)
Odds ratio (95% confidence interval)
Unadjusted conditional 
risk analysis*
Conditional risk analysis 
adjusted for risk factors†
(n = 144/144)* (n = 144/144)†
Vitamin B6 (Pyridoxal 5’-phosphate), nmol/L ‡
 1 (5.31–25.4) 47 (33) 35 (24) 1.00 (referent) 1.00 (referent)
 2 (25.4–35.9) 40 (28) 31 (22) 0.86 (0.44 to 1.67) 0.80 (0.40 to 1.61)
 3 (35.9–51.9) 28 (19) 40 (28) 0.46 (0.22 to 0.95) 0.48 (0.23 to 1.01)
 4 (51.9–435) 29 (20) 38 (26) 0.50 (0.25 to 1.01) 0.47 (0.23 to 0.99)
Ptrend§ .02 .07
* Assessed by analyzing renal cell carcinoma (RCC) cases and their individually matched controls by conditional logistic regression, conditioning on individual case 
set. MCCS = Melbourne Collaborative Cohort Study; RCC = renal cell carcinoma.
† Assessed by analyzing RCC cases and their individually matched controls by conditional logistic conditioning on individual case set, and adjusting for waist-to-hip 
ratio (continuous), smoking status (never/former/current), plasma cotinine (continuous), and alcohol intake at recruitment (g/day).
‡ Quartile cutoff points were determined based on the plasma level distribution of each biomarker for 556 individually matched controls in the European Prospective 
Investigation into Cancer and Nutrition study
§ Ptrend assessed by the base 2 logarithm of plasma concentrations. All statistical tests were two-sided.
Figure 1. Forest plot showing overall odds ratios of renal cell carci-
noma (RCC) for the base 2 logarithm of plasma vitamin B6 for the 
European Prospective Investigation into Cancer and Nutrition (EPIC) 
study, the Melbourne Collaborative Cohort Study (MCCS), as well as 
further stratified within the EPIC study alone. a, RCC cases and controls 
included in each stratified analysis (control group 2 was included). 
b, Odds ratios (ORs) were assessed by unconditional logistic regres-
sion by including the base 2 logarithm of plasma concentrations (ORs 
indicate relative risks of a doubling in plasma concentrations), and 
where relevant adjusted for age, sex, and country; the black dots 
indicate the ORs and the horizontal lines indicate the 95% confidence 
intervals. All statistical tests were two-sided. c, Pheterogeneity indicates 
results of chi-square test assessing the null hypothesis of ORs being 
identical. The heterogeneity test for the replication analysis indi-
cates any difference between the overall OR estimates of EPIC and 
MCCS. df = degrees of freedom.
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B6. Homocysteine also showed some association with all-cause 
mortality (Ptrend  =  .04), but adjusting for potential confounders 
attenuated this association.
We replicated the results of vitamin B6 with RCC survival in 
MCCS (57 deaths in total), the all-cause mortality HR4vs1 estimate 
being 0.56 (95% CI = 0.27 to 1.17), and a doubling in vitamin B6 
concentrations was associated with approximately 30% lower risk of 
death (HRlog2 = 0.69, 95% CI = 0.52 to 0.93, Ptrend = .02), and this esti-
mate remained unchanged after adjusting for potential confounders 
(HRlog2 = 0.69, 95% CI = 0.50 to 0.95, Ptrend =  .02). Similarly as in 
EPIC, for RCC cause-specific mortality in the MCCS (36 deaths) 
the association was strengthened (HRlog2 = 0.54, 95% CI = 0.35 to 
0.85, Ptrend = .008).
Within the EPIC case series, stage at diagnosis was only 
available for 45% of cases, though the characteristics of cases 
with and without information on tumor stage were similar 
(Supplementary Table  5, available online). Within the subset 
of cases with stage available, an association between B6 and 
Table 4. Hazard ratios of all-cause mortality for RCC cases for quartiles of plasma vitamins B2, B6, folate, B12, and homocysteine and 
methionine
Quartile (range) Deceased*, No. (%) Alive*, No. (%) Person-years
Hazard ratio (95% confidence interval)
Minimally 
adjusted†
Adjusted for risk 
factors‡
Vitamin B2 (Riboflavin), nmol/L§
 1 (2.57–9.83) 50 (24) 111 (32) 744.1 1.00 (referent) 1.00 (referent)
 2 (9.84–14.34) 52 (25) 75 (22) 602.8 1.23 (0.83 to 1.82) 1.32 (0.88 to 1.98)
 3 (14.35–22.16) 48 (23) 85 (25) 528.9 1.01 (0.68 to 1.52) 1.09 (0.72 to 1.66)
 4 (22.19–416.79) 55 (27) 73 (21) 501.4 1.19 (0.80 to 1.77) 1.38 (0.91 to 2.09)
Ptrend‖ .75 .61
Vitamin B6 (Pyridoxal 5’-phosphate), nmol/L§
 1 (5.95–25.37) 90 (44) 116 (34) 890.4 1.00 (referent) 1.00 (referent)
 2 (25.43–35.9) 51 (25) 83 (24) 576.5 0.87 (0.61 to 1.22) 0.87 (0.61 to 1.24)
 3 (35.92–51.88) 37 (18) 84 (24) 530.8 0.64 (0.43 to 0.94) 0.66 (0.44 to 0.99)
 4 (51.92–436.13) 27 (13) 61 (18) 379.5 0.57 (0.37 to 0.87) 0.59 (0.37 to 0.93)
Ptrend‖ <.001 .004
Vitamin B9 (Folate), nmol/L§
 1 (0.2–8.4) 54 (26) 97 (28) 697.0 1.00 (referent) 1.00 (referent)
 2 (8.41–11.84) 63 (31) 74 (22) 501.5 1.47 (1.02 to 2.13) 1.53 (1.04 to 2.24)
 3 (11.86–17.25) 46 (22) 85 (25) 594.9 0.92 (0.61 to 1.37) 1.00 (0.66 to 1.51)
 4 (17.27–109.35) 42 (20) 87 (25) 580.5 0.86 (0.57 to 1.30) 0.96 (0.62 to 1.47)
Ptrend‖ .45 .88
Vitamin B12 (Cobalamin), pmol/L§
 1 (75.16–281.28) 61 (30) 90 (26) 638.9 1.00 (referent) 1.00 (referent)
 2 (281.37–343.39) 57 (28) 90 (26) 600.5 0.94 (0.64 to 1.36) 0.96 (0.66 to 1.41)
 3 (343.51–419) 46 (22) 88 (26) 595.5 0.75 (0.50 to 1.13) 0.75 (0.49 to 1.14)
 4 (419.35–5000) 41 (20) 75 (22) 539.1 0.81 (0.54 to 1.21) 0.93 (0.61 to 1.41)
Ptrend‖ .18 .58
Methionine, µmol/L§
 1 (2.1–21.48) 63 (31) 82 (24) 657.7 1.00 (referent) 1.00 (referent)
 2 (21.5–25) 49 (24) 115 (33) 765.7 0.68 (0.46 to 0.99) 0.74 (0.50 to 1.10)
 3 (25.01–28.94) 43 (21) 71 (21) 455.3 0.85 (0.57 to 1.27) 0.96 (0.63 to 1.44)
 4 (28.95–71.4) 50 (24) 76 (22) 498.4 0.96 (0.65 to 1.41) 0.99 (0.67 to 1.47)
Ptrend‖ .95 .67
Homocysteine, µmol/L§
 1 (3.68–8.03) 36 (18) 103 (30) 658.3 1.00 (referent) 1.00 (referent)
 2 (8.04–9.87) 58 (28) 96 (28) 677.6 1.34 (0.88 to 2.05) 1.30 (0.85 to 2.00)
 3 (9.88–11.94) 46 (22) 68 (20) 492.5 1.44 (0.92 to 2.25) 1.38 (0.88 to 2.16)
 4 (11.95–64.88) 65 (32) 77 (22) 548.8 1.56 (1.02 to 2.40) 1.46 (0.94 to 2.25)
Ptrend‖ .04 .11
* Vital status for RCC case at the last follow-up.
† Assessed by analyzing renal cell carcinoma (RCC) cases by Cox-proportional hazards regression, adjusting for country, sex, and age at diagnosis. RCC = renal cell 
carcinoma.
‡ Assessed by analyzing RCC cases by Cox-proportional hazards regression after multiple imputation of missing covariate data, adjusting for country, sex, and age 
at diagnosis, and further by quartiles of vitamin B6 (cutoffs defined in controls), hypertension (yes/no), waist-to-hip ratio (quartiles), educational attainment (four 
categories), smoking status (never/former/current), plasma cotinine (quartiles defined by the distribution for current smokers), alcohol intake at recruitment (g/
day) and body mass index (three categories were defined: <25 kg/m2; 25–30 kg/m2, >30 kg/m2, in order to have a reasonable distribution of body mass index in 
each group). A corresponding sensitivity analysis is also provided in Supplementary Table 3 (available online) where participants with missing covariate data were 
excluded.
§ Quartile cutoff points were determined based on the plasma level distribution of each biomarker for 556 individually matched controls.
‖ Ptrend assessed by the base 2 logarithm of plasma concentrations. All statistical tests were two-sided.
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mortality was evident before adjusting for stage (HRlog2 = 0.67, 
95% CI = 0.50 to 0.91). As expected, adjusting for stage partly 
attenuated this association (HRlog2  =  0.81, 95% CI  =  0.60 to 
1.10). Similarly in MCCS for which stage was available for 
94% of cases, adjusting for stage attenuated the HR estimates 
(HRlog2 = 0.81, 95% CI = 0.55 to 1.20).
Discussion
We investigated if differences in prediagnostic circulating concen-
trations of B vitamins and additional biomarkers of the one-carbon 
metabolism were associated with differences in risk of RCC and related 
mortality. We found that subjects with higher plasma concentrations 
of vitamin B6 had a clear decrease in risk of subsequent RCC in two 
separate cohorts, as well as improved survival following diagnosis.
To date, only one prospective study assessing circulating con-
centrations of Vitamin B6 and RCC has been published (11). This 
study was conducted on 224 RCC case-control pairs nested within 
the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention 
Study and did not, in contrast to our finding, report an associa-
tion between vitamin B6 and risk. In our current EPIC study based 
on 556 prospectively collected case-control pairs, higher vitamin 
B6 concentrations were clearly associated with reduced RCC inci-
dence, with subjects in the top quartile having approximately half 
the risk of developing the disease compared with subjects in the 
bottom quartile. When we externally replicated these EPIC results 
using the independent MCCS cohort from Melbourne, Australia, 
we observed nearly identical associations.
The ATBC study recruited participants within a homogene-
ous population of Finnish men for randomized supplementation 
with alpha-tocopherol, beta-carotene or placebo (23–25), whereas 
the EPIC study is a population-based observational study where 
recruitment took place across 10 Western European countries. 
The implications of these differences in study design and source 
populations are unclear, but may complicate direct comparisons 
between the studies (12). The biochemical measurements of vita-
min B6 were also performed using different methodologies, ATBC 
applying the tyrosine decarboxylase assay and the EPIC and MCCS 
studies using liquid chromatography/tandem mass spectrometry. 
While both methods provide measurements of the active form of 
vitamin B6 (pyridoxal-5’ phosphate), we note that ATBC controls 
had approximately 25% lower concentrations of vitamin B6 than 
did current smoking EPIC controls. It is unclear whether these 
differences explain the contrasting results, but several observations 
within the current study suggest that our findings were not because 
of chance or bias. For instance, the association between vitamin B6 
concentrations and risk was nearly identical when comparing the 
cases with a separate control population, as well as when separately 
analyzing the independent cases and controls from the MCCS 
cohort. Taken together, these observations indicate that the asso-
ciation of vitamin B6 with risk is: 1) statistically robust and con-
sistent across distinct European and Australian populations, 2) not 
because of random fluctuations in the case or control populations, 
and 3) not because of differential storage conditions or preanalyti-
cal treatment of cases and controls.
Several established risk factors for RCC could theoretically 
explain the association of vitamin B6 concentrations with risk, 
including tobacco smoking and obesity related factors, but the 
OR estimates were at most marginally affected when adjusting for 
these factors. Stratified analysis also showed that the decrease in 
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Figure 2. Cumulative survival curves of all-cause mortality in European 
Prospective Investigation into Cancer and Nutrition (EPIC) for study par-
ticipants diagnosed with renal cell carcinoma (RCC) by quartiles of pre-
diagnostic plasma vitamin B6. Cumulative survival curves of all-cause 
mortality for study participants diagnosed with RCC by prediagnostic 
plasma concentrations of vitamin B6 (quartiles based on the distribution 
for the controls). The smooth lines depict survival functions calculated 
from a flexible parametric survival model with proportional hazards for 
vitamin B6 quartiles. The scattered points are Kaplan-Meier estimates of 
the survival functions, evaluated at the time of death for each failure.
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risk was evident up to 10 years after blood draw, suggesting that 
prediagnostic malignancies are unlikely to explain the results. We 
note that the association with risk was more prominent for smokers 
than never- and former smokers and for subjects without hyperten-
sion than for those with hypertension. While tobacco smoking is 
considered an established risk factor of RCC, it does not confer a 
particularly large increase in risk, current smokers having approxi-
mately a 50% risk increase compared with never smokers. That the 
effect estimate of the association between vitamin B6 and risk was 
twice that of being a current smoker would seem to rule out the 
possibility that tobacco exposure could be the underlying explana-
tion for the observed association with vitamin B6. We were also 
able to control for circulating cotinine as a biomarker for recent 
tobacco exposure among current smokers. While adjustment for 
potential confounders did not affect the estimates substantially in 
either the EPIC or MCCS samples, we note that the set of poten-
tial confounders considered was the same in each study. As such, 
we cannot completely exclude the possibility that confounding by 
other unknown risk factors may partially account for the observed 
associations.
Our analysis also indicated that RCC cases with higher predi-
agnostic plasma B6 concentrations experience improved survival, 
the hazard ratio comparing the top and bottom quartiles being 
0.57, an observation similar to the corresponding association with 
risk. While we mainly focused the survival analysis on all-cause 
mortality, an analysis of cause-specific mortality indicated that the 
association of B6 was driven by deaths caused by RCC. Indeed, no 
association between vitamin B6 and all-cause mortality was discern-
ible in controls. Subsequent survival analyses among the cases from 
MCCS resulted in very similar hazard ratio estimates of all-cause 
mortality as in EPIC, thus providing an external replication that 
higher vitamin B6 was associated with improved survival. Similar to 
the EPIC analysis, the hazard ratio estimates were notably stronger 
in MCCS when considering cause-specific mortality of RCC.
We had limited information on stage at diagnosis for cases, 
being 45% complete in EPIC and 94% in MCCS, but adjusting for 
stage in these subsets provided similar and partly attenuated HR 
estimates. This result indicates that the survival benefit for subjects 
with higher vitamin B6 is at least partially mediated through stage. 
One interpretation of these findings is that lower B6 levels contrib-
ute to a greater risk of developing a more aggressive form of kidney 
cancer that presents with a later stage.
The current study was primarily initiated based on the hypothesis 
of one-carbon metabolism being important in renal cell carcinoma 
(9). However, multiple pathways implicated in cancer development 
are dependent on vitamin B6, examples of which include the tryp-
tophan metabolism pathway, which is involved in immune function 
and inflammatory processes (26–28), as well as cell proliferation, 
angiogenesis, and oxidative stress (29), the latter being particularly 
relevant in smoking-related cancers. Our results should therefore 
not be taken as evidence for a causal role of dietary intake of vita-
min B6 in RCC aetiology (30). Indeed, dietary intake of vitamin 
B6 is not strongly related to circulating vitamin B6 levels and 
has not been associated with RCC risk (31,32). This observation 
would seem to warrant further research on lifestyle and metabolic 
determinants of circulating vitamin concentrations. Indeed, given 
the number of enzymatic reactions that are dependent on vitamin 
B6—over 100 having been identified to date (33,34)—adopting a 
more agnostic approach, such as metabolomics-based methodolo-
gies, may shed further light on the metabolic pathways involving 
vitamin B6 in the pathogenesis of renal cell carcinoma. Such an 
approach might also benefit from the use of multiple assessments 
per research participant in order to examine the extent to which 
within-person variability affects estimated associations between 
metabolites and risk
High circulating concentrations of vitamin B6 were strongly 
associated with decreased risk of RCC. Our results also 
 suggest a potentially important association with survival after 
RCC  diagnosis. Further elucidating the metabolic pathways 
 underlying this relationship and the extent to which it can be 
influenced by changes in lifestyle may suggest preventive strat-
egies for RCC and other cancers, as well as improved cancer 
survival.
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